-
Uncategorized1 month ago
Amazon adds Ozempic pill to same-day prescription drug kiosks
The Ozempic pill is coming to Amazon Pharmacy’s prescription drug kiosks. It’s an expansion for the kiosks, which operate like vending machines and have been stocking...
-
Uncategorized1 month agoOfficial leading CDC’s cruise ship program retires
WASHINGTON — The top U.S. official responsible for public health on cruise ships is stepping down, according to an internal Centers for Disease Control and Prevention...
-
Uncategorized1 month ago
EnGene’s shares crash on updated pivotal bladder cancer data
EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The Canadian...
-
Uncategorized1 month agoAngelini to buy Catalyst in $4B play for rare neuro drugs
The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S. Read...
-
Uncategorized1 month ago
FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit
The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the...
-
Uncategorized1 month agoSTAT+: More political interference at the FDA?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your...
-
Uncategorized1 month ago
Angelini inks $4.1B Catalyst buy to enter US rare disease market
Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.
-
Uncategorized1 month ago
Gilead wipes out most of Arcellx workforce
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder happening in 2027.
-
Uncategorized1 month ago
Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany
Plus, news about FDA’s one-day inspections and BioMADE: 🇵🇷 Amgen pours another $300M into Puerto Rico: The funds will be used to bolster its biologics production...
-
Uncategorized1 month agoOvercoming drug resistance with General Oncology
DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and the company’s activities in the space. RA: Why has pancreatic cancer remained so difficult...
